Showing results (261-270 of 296) with videos related to

Sort By:
Pageof 30
Alimentary Pharmacology & Therapeutics|March 22, 2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver diseaseRohit Loomba, Ginger Clark, Jeff Teckman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Pageof 30